Tissue-specific features of innate lymphoid cells in antiviral defense

Citation

Verified title: Tissue-specific features of innate lymphoid cells in antiviral defense
Publication year: 2024
DOI: 10.1038/s41423-024-01161-x
Metadata source: crossref-doi (confidence: high)
Original local title: Tissue-specific features of innate lymphoid cells in antiviral defense

Ingest Mode

Mode: focused manual crystallization mode
Meaning: this source page was manually reviewed for source text, model context, assay directness, and claim boundaries.
Durable synthesis status: selected source-specific claims were propagated into entity/topic/digest pages only where evidence strength and context labels are preserved.

Source Type

review of tissue-specific innate lymphoid cell features in antiviral defense
Evidence profile: review-level synthesis across NK cells, ILC1s, ILC2s, ILC3s, tissue microenvironments, and virus infection contexts.
Knowledge note status: source-reviewed review note suitable for conceptual framing, not primary mechanistic confidence.

Evidence Profile

Overall confidence: medium for review-level framing that antiviral ILC functions are tissue-conditioned; low for any single mechanism unless supported by the cited primary source.
Evidence tags: #source/review #species/mixed #tissue/lung #cell/ILC1 #cell/ILC2 #cell/ILC3 #cell/NK #outcome/infection #outcome/repair #axis/ILC_lung_infection #status/focused_crystallization
Primary biological axis: tissue microenvironment shapes ILC antiviral defense, repair, and immunopathology across barrier sites.

Why It Matters Here

This review helps keep the lung viral-infection branch biologically cautious: antiviral defense is not one ILC function but a tissue- and virus-conditioned network in which NK cells, ILC1s, ILC2s, and ILC3s have different evidence strength.

Key Findings

The review frames ILC antiviral biology as tissue-specific rather than universal.
It emphasizes that NK-cell antiviral mechanisms have the strongest direct antiviral lineage, while helper-like ILCs often shape inflammation, repair, and tissue response.
It is useful for placing lung viral ILC2 repair and pathology sources in a broader antiviral context.
It should not be used as a substitute for primary influenza, RSV, rhinovirus, or SARS-CoV-2 source notes.

Claim-Level Confidence

Medium confidence: tissue context is a valid organizing principle for antiviral ILC interpretation.
Low-to-medium confidence: individual lung-virus mechanisms should be upgraded only when matched to primary pulmonary sources.
Low confidence: review-level statements should not be used as primary evidence for therapeutic claims.

Methods and Context

Source type: narrative review.
Evidence directness: conceptual and citation-routing rather than direct experimental evidence.
Best wiki use: reading-route support for lung infection, antiviral defense, and repair-versus-pathology framing.

Caveats

Review-level evidence should remain clearly labeled.
Distinguish direct antiviral killing from helper-like effects on inflammation, repair, or barrier response.
Virus family, tissue, and timing matter; do not generalize one viral model to all respiratory infection.

Contradiction and Supersession

Contradiction status: complements primary respiratory virus source notes by providing tissue-specific framing.
Supersession status: not superseded; not a substitute for primary source claims.